Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.
Meghan J MooradianJames M ClearyAnita Giobbie-HurderLancia N F DarvilleAparna Raj ParikhElizabeth I BuchbinderJustine V CohenDonald P LawrenceGeoffrey I ShapiroHarold KeerHelen X ChenSusan Percy IvyKeiran S M SmalleyJohn M KoomenRyan J SullivanPublished in: Cancer (2023)
HSP90 inhibition combined with BRAF/MEK inhibition was safe and produced evidence of modest disease control in a heavily pretreated population. Additional translational work may identify tumor types and resistance mechanisms that are most sensitive to this approach.